An Open-label, Cross-over, Pharmacokinetic Study to Assess the Safety and Pharmacokinetics of Transdermal Granisetron (Sancuso Patch) and IV Granisetron in a Pediatric Oncology Population (Aged 13 to 17 Years)
Phase of Trial: Phase I
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Granisetron (Primary) ; Granisetron (Primary)
- Indications Chemotherapy-induced nausea and vomiting
- Focus Pharmacokinetics
- Sponsors Kyowa Kirin International
- 19 Jan 2017 Status changed from active, no longer recruiting to completed.
- 16 Dec 2015 Planned End Date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov.
- 16 Dec 2015 Planned primary completion date changed from 1 May 2014 to 1 May 2016 as reported by ClinicalTrials.gov.